NasdaqGS:ANGOMedical Equipment
AngioDynamics (ANGO) Margins Stay Negative In Q2 2026 And Test Bullish Turnaround Hopes
AngioDynamics (ANGO) just posted another unprofitable quarter, reporting Q2 2026 revenue of US$79.4 million, a basic EPS loss of US$0.15, and net income loss of US$6.35 million, against a trailing twelve month revenue base of US$307.3 million and a loss of US$27.71 million. Over recent quarters the company has reported revenue of US$72.8 million in Q2 2025, US$72.0 million in Q3 2025, US$80.2 million in Q4 2025, US$75.7 million in Q1 2026, and US$79.4 million in Q2 2026. Quarterly EPS losses...